Valuation: Alumis Inc.

Market Cap 919M 806M 762M 694M 1.3B 88.08B 1.31B 9.11B 3.53B 45B 3.45B 3.38B 145B P/E 2026 *
-2.17x
P/E 2027 * -2.52x
Enterprise Value 203M 178M 168M 153M 287M 19.46B 289M 2.01B 780M 9.94B 762M 746M 31.94B EV / Sales 2026 *
32.4x
EV / Sales 2027 * 16.6x
Free-Float
96.45%
Yield 2026 *
-
Yield 2027 * -
1 day-2.25%
1 week-11.77%
Current month-68.04%
1 month-68.86%
3 months-74.32%
6 months-65.51%
Current year-28.59%
1 week 6.91
Extreme 6.91
8.14
1 month 6.91
Extreme 6.91
22.54
Current year 6.91
Extreme 6.91
31.35
1 year 3.76
Extreme 3.76
31.35
3 years 2.76
Extreme 2.7601
31.35
5 years 2.76
Extreme 2.7601
31.35
10 years 2.76
Extreme 2.7601
31.35
Manager TitleAgeSince
Chief Executive Officer 61 2021-09-22
Director of Finance/CFO 60 2022-04-30
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 60 2021-05-31
Chairman 61 2021-09-22
Director/Board Member 55 2022-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/8/26
Samsara BioCapital LLC
SellCompany -642,712 0.5207%
9/4/26 Other

Director

0 0%
8/3/26 Sell

Chief Technology Officer

-2,447 0.0020%
Change 5-day change 1-year change 3-year change Capi.($)
-2.46%-11.77%+76.46% - 919M
-3.30%+1.50%+57.79%+85.24% 72.26B
-0.07%-2.53%+38.42%+87.21% 60.24B
+0.75%+0.75%+34.85%+21.09% 27.73B
-1.03%-3.76%-17.79%+352.06% 25.73B
-1.62%-1.01%-1.11%-4.92% 24.75B
+0.31%+1.15%+24.78%-8.23% 20.74B
-1.70%-2.12%+150.24%+323.16% 15.06B
-0.23%+1.37%+42.98%+159.07% 14.41B
-2.53%-8.15%-8.15%+483.59% 14.23B
Average -1.12%-0.47%+39.85%+166.47% 27.61B
Weighted average by Cap. -1.20%+0.28%+37.39%+126.50%

Financials

2026 *2027 *
Net sales 6.26M 5.49M 5.19M 4.73M 8.85M 600M 8.92M 62.1M 24.05M 307M 23.51M 23M 985M 24.33M 21.35M 20.17M 18.38M 34.4M 2.33B 34.65M 241M 93.48M 1.19B 91.37M 89.39M 3.83B
Net income -427M -375M -354M -323M -604M -40.95B -608M -4.24B -1.64B -20.92B -1.6B -1.57B -67.24B -409M -359M -339M -309M -578M -39.17B -582M -4.05B -1.57B -20.01B -1.53B -1.5B -64.31B
Net Debt -716M -628M -593M -541M -1.01B -68.62B -1.02B -7.1B -2.75B -35.06B -2.69B -2.63B -113B -514M -451M -426M -388M -727M -49.25B -732M -5.1B -1.97B -25.16B -1.93B -1.89B -80.87B
Logo Alumis Inc.
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Employees
238
Date Price Change Volume
26-09-28 US$6.970 -1.83% 93,068
26-09-25 US$7.100 -2.61% 1,723,962
26-09-24 US$7.290 -2.02% 2,605,339
26-09-23 US$7.440 -8.26% 2,694,970
26-09-22 US$8.110 +2.66% 2,524,709
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
7.100USD
Average target price
32.12USD
Spread / Average Target
+352.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALMS Stock